Cue Biopharma And Boehringer Ingelheim Announce Strategic Partnership To Develop And Commercialize First-in-Class Bispecific T Cell-Engaging B Cell Depletion Therapy CUE-501 For Autoimmune And Inflammatory Diseases, Aiming For Earlier Intervention And Long-Term Disease Control

• Partnership bolsters Boehringer's autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need.
  
  
  
   
• The agreement focuses on further research and development of a novel, first-in-class bispecific compound for T cell mediated targeted depletion of specific B cells to address autoimmune and inflammatory diseases.
  
  
  
   
• The candidate compound has the potential to reach patients with autoimmune diseases earlier in their treatment journey and achieve long-term disease control by reducing targeted B cell populations.
  
  
  
   

INGELHEIM, Germany and BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Boehringer Ingelheim and Cue Biopharma, Inc. (NASDAQ:CUE) today announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma's CUE-501 product candidate, a differentiated B cell depletion therapy for autoimmune diseases. Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the potential treatment of autoimmune and inflammatory diseases.

Cue Biopharma's preclinical candidate molecule binds to a B cell specific membrane protein and in parallel selectively engages virus-specific memory killer T cells. This enables it to selectively deplete B cells and dampen autoimmune and inflammatory processes, potentially offering improved benefit and safety versus other therapeutic approaches targeting B cells.